Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, B. Al Benson, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. KoSrinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, Susan Darlow

Research output: Contribution to journalReview articlepeer-review

775 Scopus citations

Abstract

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresect-able disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adeno-carcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

Original languageEnglish
Pages (from-to)1028-1061
Number of pages34
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number8
DOIs
StatePublished - Aug 2017

Fingerprint

Dive into the research topics of 'Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology'. Together they form a unique fingerprint.

Cite this